Drug Trial Radar · NCT05492578
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,856
Actual
Start
Aug 22, 2022
Primary completion
Jan 22, 2029
Study completion Jan 22, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants rolling over from EFC17599 and EFC17600, and responder participants enrolling through screening from DRI17366 will be initiated into drug withdrawal (with no drug administration) at LTS17367 baseline visit to monitor durability of treatment response. If these responder participants relapse during LTS17367, they will have treatment restored. Non-responder participants rolling over from EFC17599 or EFC17600, and non-responder participants enrolling through screening from DRI17366 will have treatment administration from LTS17367 baseline. Participants rolling over from DRI17366, SFY17915 and INT18404 will also have treatment administration from LTS17367 baseline. Remote visits with home dosing are allowed for the purpose of study drug administration, when applicable. In the case of remote visit with home dosing, the participant or a caregiver may administer study drug after appropriate training. Alternatively, if needed, and based on the investigator's judgement, home visits with healthcare professional assistance or on-site study drug administration visits can be performed. Where participants discontinue amlitelimab permanently during LTS17367, safety follow up will be performed for a minimum of 140 days from the last amlitelimab administration.
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Topical corticosteroidsDrug
Pharmaceutical form: Topical Route of administration: Topical
Topical calcineurin inhibitorsDrug
Pharmaceutical form: Topical Route of administration: Topical
Oral corticosteroidsDrug
Pharmaceutical form: Oral Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who experienced treatment-emergent adverse event (TEAE)Time frame: Baseline to Week 332
Locations
392 sites in 29 countries. Site status is shown where the registry gives one.
Allervie Clinical Research - Birmingham- Site Number : 8401101
Birmingham, Alabama
Cahaba Dermatology & Skin Health Center- Site Number : 8401066
Birmingham, Alabama
Center for Dermatology and Plastic Surgery- Site Number : 8401119
Scottsdale, Arizona
Scottsdale Clinical Trials- Site Number : 8401149
Scottsdale, Arizona
Eclipse Clinical Research- Site Number : 8401158
Tucson, Arizona
Arkansas Research Trials- Site Number : 8401244
North Little Rock, Arkansas
Orange County Clinical Trials- Site Number : 8401271
Anaheim, California
Encino Research Center- Site Number : 8401042
Encino, California
First OC Dermatology- Site Number : 8401025
Fountain Valley, California
Center for Dermatology Clinical Research- Site Number : 8401018
Fremont, California
Marvel Clinical Research- Site Number : 8401102
Huntington Beach, California
Sunwise Clinical Research - Lafayette- Site Number : 8401022
Lafayette, California
Antelope Valley Clinical Trials- Site Number : 8401099
Lancaster, California
Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027
Lomita, California
Long Beach Clinical Trials- Site Number : 8401188
Long Beach, California
Dermatology Research Associates- Site Number : 8401092
Los Angeles, California
LA Universal Research Center- Site Number : 8401064
Los Angeles, California
University Dermatology Trials- Site Number : 8401339
Newport Beach, California
Cura Clinical Research - Oxnard- Site Number : 8401142
Oxnard, California
Southern California Dermatology- Site Number : 8401043
Santa Ana, California
Clinical Science Institute- Site Number : 8401028
Santa Monica, California
Paradigm Clinical Research - Wheat Ridge- Site Number : 8401245
Wheat Ridge, Colorado
UConn Health - Farmington- Site Number : 8401115
Farmington, Connecticut
Encore Medical Research of Boynton Beach- Site Number : 8401030
Boynton Beach, Florida
Pediatric Skin Research- Site Number : 8401198
Coral Gables, Florida
St. Jude Clinical Research- Site Number : 8401287
Doral, Florida
Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111
Fort Myers, Florida
Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286
Fort Myers, Florida
Direct Helpers Research Center- Site Number : 8401056
Hialeah, Florida
Doral Medical Research - Hialeah- Site Number : 8401094
Hialeah, Florida
Apex Clinical Research - Jacksonville- Site Number : 8401332
Jacksonville, Florida
Clever Medical Research- Site Number : 8401160
Miami, Florida
Miami Dermatology and Laser Research- Site Number : 8401086
Miami, Florida
Medical Research Center of Miami II- Site Number : 8401019
Miami, Florida
Acevedo Clinical Research Associates- Site Number : 8401088
Miami, Florida
Future Care Solution - Miami- Site Number : 8401144
Miami, Florida
Sanchez Clinical Research- Site Number : 8401095
Miami, Florida
Florida International Research Center- Site Number : 8401091
Miami, Florida
Savin Medical Group - Miami Lakes- Site Number : 8401085
Miami Lakes, Florida
Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8401109
Miami Lakes, Florida
Showing 40 of 392 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.